Toripalimab, the first domestic PD-1 antibody with broad antitumor activity marketed in China (11), was approved for marketing by National Medical Products Administration in September 2022 for first-line treatment of advanced non-squamous NSCLC without EGFR/ALK driver mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.